Related Experiment Videos
[Preparation of prothrombin complex concentrates with reduced thrombogenicity]
Folia Haematologica (Leipzig, Germany : 1928)
|January 1, 1982
Summary
Adding heparin to human citrate plasma reduces the thrombogenicity of prothrombin complex concentrates. This method, involving heparin and antithrombin III, ensures no procoagulatory activity in the final preparation.
Area of Science:
- Biochemistry
- Hematology
- Biotechnology
Context:
- Prothrombin complex concentrates (PCCs) are crucial in treating coagulation factor deficiencies.
- The inherent thrombogenicity of PCCs poses a significant clinical risk.
- Current methods for mitigating PCC thrombogenicity require optimization.
Purpose:
- To investigate the efficacy of heparin addition in reducing the thrombogenicity of prothrombin complex concentrates.
- To establish optimal conditions for heparin administration during PCC preparation.
- To confirm the absence of procoagulatory activity in heparin-modified PCCs.
Summary:
- Heparin addition to human citrate plasma, ideally before or during prothrombin complex adsorption, effectively diminishes PCC thrombogenicity.
- The timing, dosage, and method of heparin addition are adaptable based on initial material and processing conditions.
- Preparations utilizing buffer solutions with heparin and antithrombin III demonstrated no procoagulatory effects.
Impact:
- Provides a safer alternative for prothrombin complex concentrate preparation.
- Enhances the clinical applicability of prothrombin complex concentrates by reducing thrombotic risks.
- Offers a novel approach to modifying blood-derived products for improved safety profiles.